When patients are in need, we answer the call

Merck’s Board of Directors approves expansion of our plant in Durham, North Carolina, to help patients

January 27, 2021

Share this article

article hero thumbnail

In 2012, Merck unexpectedly became the only source for the U.S. and many countries of one of our older cancer medicines after other companies that made similar medicines stopped production. All of Merck’s supplies of this medicine come from our plant in Durham, North Carolina, where our dedicated manufacturing colleagues have worked around the clock to increase production.  Even so, increasing global demand has outpaced our current maximum manufacturing capabilities.  

When patients are in need, we answer the call. Our Board of Directors has approved plans to construct a new manufacturing facility in Durham to significantly expand our production capacity for this medicine – to triple our current manufacturing capacity, which is expected to support the anticipated demand for the foreseeable future. This investment reaffirms Merck’s longstanding commitment to making our medicines available for patients who need them.